Parabilis Medicines Funding: $500M Raised, Series F (2026)
Parabilis Medicines is a Biotech company based in Cambridge, Massachusetts. It has raised $500M in total funding. Latest round: Series F.
Parabilis Medicines funding overview
Parabilis Medicines is a Biotech company based in Cambridge, Massachusetts. Parabilis Medicines has raised $500M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series F announced in January 2026. The round record for Parabilis Medicines runs through 2026; nothing later has been disclosed. Investors on record include RA Capital Management, Fidelity, Janus Henderson Investors. 3 distinct backers are named across the disclosed rounds.
Parabilis Medicines at a glance
Total raised
$500M
Latest round
Series F
Latest round date
January 2026
Industry
Biotech
Headquarters
Cambridge, Massachusetts
Notable investors
RA Capital Management, Fidelity, Janus Henderson Investors
Frequently asked about Parabilis Medicines funding
How much has Parabilis Medicines raised?
Parabilis Medicines has raised $500M in total disclosed funding across the rounds on record.
Who has invested in Parabilis Medicines?
RA Capital Management, Fidelity, Janus Henderson Investors are named among the investors backing Parabilis Medicines.
What was the latest Parabilis Medicines funding round?
The most recent disclosed round is a Series F, announced in January 2026.
Where is Parabilis Medicines based?
Parabilis Medicines is based in Cambridge, Massachusetts.
What sector does Parabilis Medicines operate in?
Parabilis Medicines is tracked under Biotech from Cambridge, Massachusetts, with $500M in disclosed funding.
When did Parabilis Medicines last raise?
The last disclosed Parabilis Medicines round closed in January 2026 at Series F.
Totals shown for Parabilis Medicines aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Cambridge and the investors behind them below.
